Healthcare -
Biotechnology - NASDAQ - US
$ 15.82
49.8 %
$ 80.8 M
Market Cap
-0.37
P/E
1. INTRINSIC VALUE
FINANCIALS
Balance Sheet
Eyenovia, Inc.
| Current Assets | 2.77 M |
| Cash & Short-Term Investments | 2.12 M |
| Receivables | 314 K |
| Other Current Assets | 332 K |
| Non-Current Assets | 901 K |
| Long-Term Investments | 0 |
| PP&E | 718 K |
| Other Non-Current Assets | 182 K |
| Current Liabilities | 16 M |
| Accounts Payable | 2.2 M |
| Short-Term Debt | 10.5 M |
| Other Current Liabilities | 3.32 M |
| Non-Current Liabilities | 718 K |
| Long-Term Debt | 718 K |
| Other Non-Current Liabilities | 0 |
EFFICIENCY
Earnings Waterfall
Eyenovia, Inc.
| Revenue | 57.3 K |
| Cost Of Revenue | 3.93 M |
| Gross Profit | -3.87 M |
| Operating Expenses | 40.9 M |
| Operating Income | -48.7 M |
| Other Expenses | 1.08 M |
| Net Income | -49.8 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Eyenovia, Inc.
| Net Income | -49.8 M |
| Depreciation & Amortization | 1.13 M |
| Capital Expenditures | -161 K |
| Stock-Based Compensation | 1.7 M |
| Change in Working Capital | -340 K |
| Others | 16.4 M |
| Free Cash Flow | -30.3 M |
Wall Street Analysts Price Targets
Eyenovia, Inc.
EYEN has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
EYEN does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Eyenovia, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
1.04 M USD 2
9-12 MONTHS
7. News
Chardan Expands into Digital Assets by Advising Strategic Crypto-Backed Financings
NEW YORK , June 18, 2025 /PRNewswire/ -- Chardan, a leading global investment banking and advisory firm, today announced an expansion into the digital asset sector, advising on and structuring a series of transactions that bridge traditional capital markets with the rapidly evolving world of blockchain and cryptocurrency. As part of its strategic push into crypto finance, Chardan has recently served as a strategic advisor and placement agent in the following notable transactions: Eyenovia's $50 Million PIPE to Acquire HYPE Tokens Chardan acted as sole placement agent in Eyenovia Inc.'s (NASDAQ: EYEN) $50 million PIPE financing.
prnewswire.com
- 2 weeks ago
Eyenovia Announces Appointment of a Strategic Advisor for Digital Asset Treasury Strategy and Amendment of Debt Agreement with Avenue Capital Group
EYEN to bring on major Hyperliquid Thought Leader to support HYPE Treasury Strategy EYEN to bring on major Hyperliquid Thought Leader to support HYPE Treasury Strategy
globenewswire.com
- 2 weeks ago
Eyenovia Announces $50 Million Investment to Launch a Hyperliquid (HYPE token) Cryptocurrency Treasury Reserve Strategy
Announces private placement EYEN to become first U.S.-based publicly listed company to hold HYPE in its treasury Hyunsu Jung appointed Chief Investment Officer and Board Member LAGUNA HILLS, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”) today announced that it has entered into a securities purchase agreement (the “SPA”) for a $50 million private placement in public equity (the “PIPE Financing”) with institutional accredited investors.
globenewswire.com
- 2 weeks ago
Eyenovia Provides Updates on Potential Merger with Betaliq and Development of the Optejet User Filled Device (UFD), and Reports First Quarter 2025 Financial Results
Eyenovia and Betaliq continue to negotiate a binding merger agreement consistent with the previously announced signed Letter of Intent
globenewswire.com
- 1 month ago
Eyenovia Provides Development Update on Optejet User Filled Device (UFD)
On track for regulatory submission seeking marketing approval of the Optejet UFD in Q4 2025 On track for regulatory submission seeking marketing approval of the Optejet UFD in Q4 2025
globenewswire.com
- 2 months ago
Eyenovia Enters into Non-Binding Letter of Intent to Effect Reverse Merger with Betaliq
Combination, if successful, would create a new publicly-listed eye care company combining Betaliq's EyeSol ® water-free drug delivery technology for glaucoma with Eyenovia's Optejet ® device platform
globenewswire.com
- 3 months ago
Eyenovia Regains Compliance with All Nasdaq Continued Listing Requirements
NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company"), an ophthalmic technology company focused on completing development of its proprietary Optejet® device, today announced that it has been informed by staff of The Nasdaq Stock Market LLC that the Company has regained compliance with all Nasdaq Capital Market continued listing requirements, including Nasdaq Listing Rule 5550(a)(2), the minimum bid price requirement rule, and Listing Rule 5810(c)(3)(A)(iii), the low priced stocks rule.
globenewswire.com
- 4 months ago
Eyenovia, Inc. Announces Debt Restructuring Including Amendment to Senior Secured Debt, Improving Cash Runway to Allow for the Evaluation of Strategic Alternatives
Amendment provides financial flexibility to the Company by deferring all interest as well as principal redemption payments through September 2025, while reducing near-term cash needs Amendment provides financial flexibility to the Company by deferring all interest as well as principal redemption payments through September 2025, while reducing near-term cash needs
globenewswire.com
- 4 months ago
Eyenovia Announces Progress on Next-Generation User-Filled Optejet Dispensing Device
Eyenovia plans to submit for U.S. device regulatory approval in Q4 of this year, marking a key step toward commercialization Eyenovia plans to submit for U.S. device regulatory approval in Q4 of this year, marking a key step toward commercialization
globenewswire.com
- 5 months ago
Eyenovia Announces 1-for-80 Reverse Stock Split
Reverse stock split, when effective, is intended to restore compliance with the Nasdaq minimum bid price requirement while Eyenovia continues to evaluate a broad range of strategic alternatives Reverse stock split, when effective, is intended to restore compliance with the Nasdaq minimum bid price requirement while Eyenovia continues to evaluate a broad range of strategic alternatives
globenewswire.com
- 5 months ago
Eyenovia Announces Leading Proxy Advisory Firms, ISS and Glass Lewis, Recommend Eyenovia Stockholders Vote “FOR” Proposed Reverse Stock Split at Upcoming Special Meeting of Stockholders
Virtual meeting scheduled for 10:00 a.m. ET on January 21st; stockholders must pre-register by 11:59 p.m. ET on January 20th Virtual meeting scheduled for 10:00 a.m. ET on January 21st; stockholders must pre-register by 11:59 p.m. ET on January 20th
globenewswire.com
- 5 months ago
Eyenovia Engages Chardan as Advisor for Review of Strategic Alternatives
Company concurrently focused on completing development of the Gen-2 user-filled Optejet® device by 3Q 2025 while reducing spend by over 60% Company concurrently focused on completing development of the Gen-2 user-filled Optejet® device by 3Q 2025 while reducing spend by over 60%
globenewswire.com
- 6 months ago
8. Profile
Summary
Eyenovia, Inc. EYEN
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 80.8 M
Dividend Yield
0.00%
Description
Eyenovia, Inc., a clinical stage ophthalmic company, engages in developing therapeutics based on its proprietary microdose array print platform technology. The company focuses on developing clinical microdosing of formulations of ophthalmic pharmaceutical agents using its Optejet branded targeted ocular delivery system. It focuses on the development of therapeutic indications for patients with progressive myopia and age-related near vision impairment or presbyopia indications; and microdose fixed combination ophthalmic pharmaceutical for mydriasis to address the eye exams with pupil dilation. The company's product candidates include MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); and MydCombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; and a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine and MicroLine in China and South Korea. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is headquartered in New York, New York.
Contact
295 Madison Avenue, New York City, NY, 10017
https://www.eyenovia.com
IPO
Date
Jan. 25, 2018
Employees
13
Officers
Mr. Enrico Brambilla
Senior Vice President of R&D
Mr. Bren Kern
Chief Operating Officer
Mr. Norbert Lowe
Senior Vice President of Commercial Operations
Dr. Tsontcho Ianchulev M.D., M.P.H., MPH
Co-Founder & Executive Director
Alexander Lobo
Investor Contact
Mr. Michael M. Rowe
Principal Financial Officer, Chief Executive Officer, President & Director